Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome )Clinical Mucopolysaccharidosis VI Clinical Trials Market | Page 2

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business
opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed
and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
View summary of this report @ http://www.radiantinsights.com/research/mucopolysaccharidosisvi-mps-vi-maroteaux-lamy-syndrome-global-clinical-trials-review-h1-2016
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy
Syndrome ) to Metabolic Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16